|
|
Post by tiberious on Feb 8, 2018 16:56:13 GMT -5
|
|
|
|
Post by mnholdem on Feb 8, 2018 17:57:23 GMT -5
Sanofi had insisted in the License and Collaboration Agreement on all rights to any GLP-1 coming out of the pipeline, so at leasts one BP thinks a Technosphere GLP-1 has value.
|
|
|
|
Post by peppy on Feb 8, 2018 18:11:04 GMT -5
|
|
|
|
Post by sayhey24 on Feb 8, 2018 18:33:35 GMT -5
So why did Al Mann lose interest in the GLP-1? At one point he was really excited. Was it the safety issues they started seeing with Byetta?
At this point with afrezza performing better than anyone expected and actually turning off the glucagon and getting the liver back in sync, it sure appears afrezza has obsoleted any need for the GLP-1s. Then again Trulicity is Lilly's new top seller and they will continue to sell it as more PWDs develop cancer.
|
|
|
|
Post by robbmo on Feb 8, 2018 18:59:44 GMT -5
So why did Al Mann lose interest in the GLP-1? At one point he was really excited. Was it the safety issues they started seeing with Byetta? At this point with afrezza performing better than anyone expected and actually turning off the glucagon and getting the liver back in sync, it sure appears afrezza has obsoleted any need for the GLP-1s. Then again Trulicity is Lilly's new top seller and they will continue to sell it as more PWDs develop cancer. I believe I read somewhere that the molecule is too big for a TI application |
|
|
|
Post by sayhey24 on Feb 8, 2018 19:17:31 GMT -5
|
|
|
|
Post by dreamboatcruise on Feb 8, 2018 19:23:49 GMT -5
And didn't Sanofi demand rights to market it in their now defunct agreement with MNKD. |
|
|
|
Post by peppy on Feb 8, 2018 20:59:49 GMT -5
And didn't Sanofi demand rights to market it in their now defunct agreement with MNKD. Sanofi had insisted in the License and Collaboration Agreement on all rights to any GLP-1 coming out of the pipeline, so at leasts one BP thinks a Technosphere GLP-1 has value. Read more: mnkd.proboards.com/thread/9534/glp-1-attempt?page=1#ixzz56ZXTnP71 |
|
|
|
Post by tiberious on Feb 8, 2018 21:19:29 GMT -5
So why did Al Mann lose interest in the GLP-1? At one point he was really excited. Was it the safety issues they started seeing with Byetta? At this point with afrezza performing better than anyone expected and actually turning off the glucagon and getting the liver back in sync, it sure appears afrezza has obsoleted any need for the GLP-1s. Then again Trulicity is Lilly's new top seller and they will continue to sell it as more PWDs develop cancer. I believe I read somewhere that the molecule is too big for a TI application Regarding other drug commercials I just watched a Jardiance commercial and the whole pitch was about reducing cardiac risk with practically nothing about its effectiveness for PWD's and the seriousness of side effects with this class. docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Jardiance/jardiance.pdf |
|
|
|
Post by peppy on Feb 8, 2018 21:35:45 GMT -5
Jardiance, love your numbers miss your legs. JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, • to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. (1) WARNINGS AND PRECAUTIONS- 5.1 Hypotension JARDIANCE causes intravascular volume contractionJ. Symptomatic hypotension may occur after initiating JARDIANCE [see Adverse Reactions (6.1)] particularly in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics. Before initiating JARDIANCE, assess for volume contraction and correct volume status if indicated. Monitor for signs and symptoms of hypotension after initiating therapy and increase monitoring in clinical situations where volume contraction is expected [see Use in Specific Populations (8.5)]. 5.2 Ketoacidosis Reports of ketoacidosis, a serious life-threatening condition requiring urgent hospitalization have been identified in postmarketing surveillance in patients with type 1 and type 2 diabetes mellitus receiving sodium glucose co-transporter-2 (SGLT2) inhibitors, including JARDIANCE. Fatal cases of ketoacidosis have been reported in patients taking JARDIANCE. JARDIANCE is not indicated for the treatment of patients with type 1 diabetes mellitus [see Indications and Usage (1)]. 5.3 Acute Kidney Injury and Impairment in Renal Function JARDIANCE causes intravascular volume contraction [see Warnings and Precautions (5.1)] and can cause renal impairment [see Adverse Reactions (6.1)]. There have been postmarketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients receiving SGLT2 inhibitors, including JARDIANCE; some reports involved patients younger than 65 years of age.
5.4 Urosepsis and Pyelonephritis
There have been postmarketing reports of serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization in patients receiving SGLT2 inhibitors, including JARDIANCE. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated [see Adverse Reactions (6)].
www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdfLess heart attack? |
|
|
|
Post by tiberious on Feb 8, 2018 21:48:57 GMT -5
Jardiance, love your numbers miss your legs. JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, • to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. (1) WARNINGS AND PRECAUTIONS- 5.1 Hypotension JARDIANCE causes intravascular volume contractionJ. Symptomatic hypotension may occur after initiating JARDIANCE [see Adverse Reactions (6.1)] particularly in patients with renal impairment, the elderly, in patients with low systolic blood pressure, and in patients on diuretics. Before initiating JARDIANCE, assess for volume contraction and correct volume status if indicated. Monitor for signs and symptoms of hypotension after initiating therapy and increase monitoring in clinical situations where volume contraction is expected [see Use in Specific Populations (8.5)]. 5.2 Ketoacidosis Reports of ketoacidosis, a serious life-threatening condition requiring urgent hospitalization have been identified in postmarketing surveillance in patients with type 1 and type 2 diabetes mellitus receiving sodium glucose co-transporter-2 (SGLT2) inhibitors, including JARDIANCE. Fatal cases of ketoacidosis have been reported in patients taking JARDIANCE. JARDIANCE is not indicated for the treatment of patients with type 1 diabetes mellitus [see Indications and Usage (1)]. 5.3 Acute Kidney Injury and Impairment in Renal Function JARDIANCE causes intravascular volume contraction [see Warnings and Precautions (5.1)] and can cause renal impairment [see Adverse Reactions (6.1)]. There have been postmarketing reports of acute kidney injury, some requiring hospitalization and dialysis, in patients receiving SGLT2 inhibitors, including JARDIANCE; some reports involved patients younger than 65 years of age.
5.4 Urosepsis and Pyelonephritis
There have been postmarketing reports of serious urinary tract infections including urosepsis and pyelonephritis requiring hospitalization in patients receiving SGLT2 inhibitors, including JARDIANCE. Treatment with SGLT2 inhibitors increases the risk for urinary tract infections. Evaluate patients for signs and symptoms of urinary tract infections and treat promptly, if indicated [see Adverse Reactions (6)].
www.accessdata.fda.gov/drugsatfda_docs/label/2016/204629s008lbl.pdfLess heart attack? I don't know but if you watch this you can "get to the heart of the matter.." www.youtube.com/watch?v=GF_JBvEH6Qc |
|
|
|
Post by dreamboatcruise on Feb 9, 2018 2:35:26 GMT -5
Jardiance, love your numbers miss your legs. Walking is so overrated   |
|
|
|
Post by sportsrancho on Feb 9, 2018 6:06:09 GMT -5
Sad to say this commercial is the best in breed in getting your attention. I see it all the time.
Makes you wonder how the doctors have time to monitor all the side effects!
|
|
|
|
Post by peppy on Feb 9, 2018 7:34:48 GMT -5
Sad to say this commercial is the best in breed in getting your attention. I see it all the time. Makes you wonder how the doctors have time to monitor all the side effects! The physicians schedule the amputation. sodium-glucose co-transporter 2 (SGLT2). |
|
|
|
Post by kc on Feb 9, 2018 14:54:46 GMT -5
Horrible.........
|
|
